Clinical trials: Weight Loss, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Weight Loss
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Obesity & Overweight
Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity
This study investigates whether temporarily blocking the ghrelin receptor affects appetite and food intake in people with overweight or obesity.
- Trial name
- H24LEAP2 (NCT07897383)
- Testing
- Liver-expressed antimicrobial peptide 2
- Volunteers
- 18 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Obesity, Interstitial Lung Disease
Feasibility of Semaglutide in Advanced Lung Disease
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question[s] it aims to answer are: 1.
- Conditions
- Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary
- Trial name
- NCT05746039
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania
Obesity, Solid Neoplasm
Weight Management in Obese Cancer Patients During Curative Active Treatment
This is a feasibility study intervention to fifty cancer patients with obesity and with newly diagnosed stage II-IV solid tumors undergoing curative treatment recruited at the Catalan Institute of Oncology (ICO) in L'Hospitalet…
- Conditions
- Obesity, Solid Neoplasm, Stage II-IV, Curative Treatment
- Trial name
- CANOBESE (NCT07058207)
- Testing
- Multimodal weight management program
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Institut d'Investigació Biomèdica de Bellvitge
Obesity in Diabetes, Obesity/Therapy
Semaglutide Treatment in Type 1 Diabetes
The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic…
- Conditions
- Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM), Insulin Sensitivity/Resistance
- Trial name
- OBES1TY (NCT06909006)
- Testing
- Semaglutide 2.4mg
- Where
- Denmark
- Volunteers
- 122 people
- Sponsor
- Nordsjaellands Hospital
Obesity, Metabolic Syndrome
Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)
This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly…
- Conditions
- Obesity, Metabolic Syndrome, Brown Adipose Tissue
- Trial name
- BAT-Sema (NCT07621640)
- Testing
- Semaglutide (Wegovy®), ¹⁸FDG-PET/CT with cold stimulation, Liver MRI (PDFF + MRE)
- Where
- 2 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Hallym University
Obesity
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and…
- Trial name
- RAMBO (NCT07010432)
- Testing
- Cagrilintide, Semaglutide
- Where
- Denmark
- Volunteers
- 144 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Weight Loss
A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function
This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531…
- Trial name
- NCT07540754
- Testing
- HRS9531 Injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Diabetes Mellitus, Type 2
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
This is a prospective cohort study evaluating the efficacy, safety, and tolerability of tirzepatide under real-world conditions in the Paraguayan population.
- Trial name
- REAL-TIRZEPY (NCT07588438)
- Testing
- Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.)
- Where
- Paraguay
- Volunteers
- 160 people
- Sponsor
- Las Rías Medical Center
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.
- Trial name
- NCT07792954
- Testing
- Berobenatide
- Where
- 34 sites in China
- Volunteers
- 300 people
- Sponsor
- Pfizer
Cancer-associated Cachexia
Visugromab in Cachexia International Trial
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia.
- Trial name
- VINCIT (NCT07112196)
- Testing
- Visugromab (CTL-002)
- Where
- 79 sites in United States, Bulgaria and 12 more
- Volunteers
- 518 people
- Sponsor
- CatalYm GmbH
Cachexia; Cancer
A Phase I Clinical Study to Evaluate the Efficacy and Safety of GB18 Injection in Patients With Tumor Cachexia
KXZY-GB18-101(1B) is an extension of KXZY-GB18-101, a first-in-human, dose-escalation trial in healthy adult participants to evaluate the safety, tolerability, PK, PD, and immunogenicity of GB18.
- Trial name
- NCT07519564
- Testing
- GB18
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Kexing Biopharm Co., Ltd.
Advanced Cancer, Cachexia
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
- Trial name
- NCT06736275
- Testing
- SXRN
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
Obesity, Weight Reduction
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without…
- Conditions
- Obesity, Weight Reduction, Cardiometabolic Risk Factors
- Trial name
- NCT07513168
- Testing
- Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Asian Institute Of Medical Sciences
Cardiovascular Diseases
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
What is the research question? Semaglutide and tirzepatide cause weight loss and blood pressure reduction. However, weight loss only partially explains the blood pressure reduction.
- Trial name
- DECODE (NCT07483801)
- Testing
- semaglutide, Tirzepatide
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Obesity (Disorder)
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
The Joule MARS study is a single center, randomized, open label clinical trial aiming to explore the metabolic adaptations that occur in response to weight management in adolescents with obesity.
- Trial name
- JOULE-MARS (NCT06852391)
- Testing
- Semaglutide Pen Injector, Behavioural Lifestyle Program (BLP)
- Where
- Canada
- Volunteers
- 74 people
- Sponsor
- McMaster University
Obesity, Muscle Loss
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass.
- Trial name
- PROACT (NCT07101939)
- Testing
- (S)-pindolol benzoate, Semaglutide
- Where
- 7 sites in Serbia
- Volunteers
- 120 people
- Sponsor
- Actimed Therapeutics Ltd
Post-bariatric Surgery
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the…
- Trial name
- GLP-1 (NCT01803451)
- Testing
- exendin-(9-39), exendin -(9-39)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Pregnancy Loss, Pregnancy Loss, Early
Efficacy of Progesterone and Low Molecular Weight Heparin in Recurrent Pregnancy Loss
This prospective, single-centre, open-label, randomized Phase III superiority trial will enroll approximately 268 women aged 18-40 years with at least two consecutive unexplained miscarriages and a singleton intrauterine…
- Trial name
- PREMISE (NCT07796737)
- Testing
- Vaginal Micronized Progesterone (Progesterone Besins), Enoxaparin (Clexane)
- Where
- Czechia
- Volunteers
- 268 people
- Sponsor
- General University Hospital, Prague
Neoadjuvant Chemotherapy, Weight Loss
Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC
Cancer-associated anorexia, a debilitating condition characterized by progressive appetite loss in oncology patients, contributes to pancytopenia, sarcopenia, and adipose tissue depletion.
- Trial name
- MATRIX (NCT06998758)
- Testing
- Megestrol Acetate
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Cachexia
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia.
- Trial name
- NCT05865535
- Testing
- AV-380
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- AVEO Pharmaceuticals, Inc.